Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

The personalized cancer vaccine market is gaining rapid momentum, driven by biotech advancements and rising demand for targeted immunotherapies. The new 2025 report analyzes key players like BioNTech, ...

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks? In this article, we are going to take a look at ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Could your gut bacteria decide how well vaccines work? A new study reveals how diet and probiotics could hold the key to stronger, longer-lasting immune protection. Study: Diet, microbiome ...

Cambridge-based Moderna played a crucial role in that effort, with federal support, rapidly developing and deploying its messenger RNA vaccine that inoculated millions against severe disease.

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock a sell? It's been nearly five years since Moderna (NASDAQ: MRNA ...

Runners-up this week include litigators at Paul Hastings, Williams & Connolly, King & Spalding, McFarland Litigation Partners ...